Lectin Mitogenicity Reduction via Chemical Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many readily available lectins pose risks due to their potential to stimulate lymphocyte proliferation, leading to inflammation, cytotoxicity, and allergic reactions, making them unsuitable for in vivo use unless carefully contained, and there is a need to reduce their T-cell mitogenicity without affecting their carbohydrate binding properties.
Innovation Solution
Chemical modification of lectin compositions under optimized conditions to reduce T-cell mitogenicity, involving the use of chemical compounds like pegylation agents to create uniformly modified lectins with reduced ability to activate T-cells and induce cytokine production, while maintaining binding affinity for saccharides and polysaccharides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lectins are used for their carbohydrate binding properties, then binding affinity is achieved, but T-cell mitogenicity causes harmful effects
Solution Approach 1:
The patent removes unmodified lectin subunits from the composition through purification steps, extracting the harmful mitogenic component while retaining the modified subunits that provide carbohydrate binding without T-cell stimulation
Solution Approach 2:
The patent chemically modifies lectin subunits by conjugating them to polymers (changing molecular weight and physical parameters), which alters their biological activity to reduce mitogenicity while preserving carbohydrate binding affinity
2Object-affected harmful factors
If chemical modification is applied to reduce mitogenicity, then T-cell activation is reduced, but uniformity of modification is compromised
Solution Approach 1:
The patent accepts that complete uniform modification is difficult to achieve, so it applies partial modification and then removes the unmodified portion through purification, achieving the desired effect without requiring perfect uniformity in the modification process
Solution Approach 2:
The patent performs chemical modification before purification, preparing the modified subunits in advance and then separating them from unmodified subunits in a subsequent step
3Object-affected harmful factors
If lectins are contained to prevent mitogenicity, then safety is improved, but device complexity increases
Solution Approach 1:
Instead of containing the lectin in a complex device structure, the patent extracts and removes the harmful unmodified subunits through purification, achieving safety through compositional control rather than structural containment
Solution Approach 2:
The patent changes the molecular parameters of the lectin through chemical modification and polymer conjugation, fundamentally altering its properties to be non-mitogenic while maintaining functionality, eliminating the need for containment devices
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified lectin compositions exhibit reduced T-cell mitogenicity, increased cell viability, and preserved carbohydrate binding properties, allowing for safer in vivo applications such as glucose sensors and controlled drug delivery systems.
Implementation Method 1
reacting the mitogenic lectin composition with a chemical compound to produce a chemically modified composition
Data Source
AI summary
Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.